ClearNote Health

Join us at Digestive Disease Week® (DDW) in Washington, DC, from May 18th to 21st, 2024!    Don't miss an insightful presentation by our Vice President, Product Development, Anna Bergamaschi:   📜 Title: Detection of High-Risk Pancreatic Cysts Using Avantect™ Blood-Based Test Abstract: #4040568 Session: Pancreatic Cystic Neoplasms, IPMN and Neuroendocrine Tumors (Clinical) 📍 Location: Hall A, Poster Hall (Walter E. Washington Convention Center) 📅 When: May 21, 2024, 12:30-1:30PM Avantect is a DNA-based blood test designed to make earlier diagnosis possible for patients at high risk for pancreatic cancer. Not attending the event, but wish to learn more? Contact us at https://lnkd.in/dp-yahs9 or visit the Avantect website: https://www.avantect.com/   #DDW2024 #Pancreaticcancer

🚨 Highlight from Abu Dhabi Global Health Week: Liquid Biopsy for Early Cancer Detection 🎤 At the Abu Dhabi Global Healthcare Week Week, Dave Mullarkey, CEO of ClearNote Health, showcased the groundbreaking Avantect Pancreatic Cancer Test. 🔈In a panel discussion led by Dr. Lawrence P Petalidis of M42 he focused on the test’s use of liquid biopsy technology for early detection in high-risk patients, including those recently diagnosed with Type 2 diabetes. 🌟 Highlighting the test’s potential, Dave illustrated how Avantect significantly enhances early cancer detection, offering advantages over traditional methods and paving the way for significantly increasing survival rates in pancreatic cancer. 🤝 The session was a clear testimony of how M42 Health, supported by the Department of Health Abu Dhabi and in close clinical collaboration with Cleveland Clinic Abu Dhabi, is pioneering advancements in oncology, driving the next generation of cancer diagnostics. #ADGHW #CancerDiagnostics #HealthcareInnovation #LiquidBiopsy

📣 📰 Exciting news from ClearNote Health! Our Avantect Pancreatic Cancer Test has been featured in an expert article on pancreatic cancer published in The Telegraph, one of the UK's leading newspapers. As noted in the article, pancreatic cancer remains one of the most challenging cancers to diagnose early and treat due to its aggressive nature and complex biological environment. Avantect is featured as a new generation of diagnostic test that offers a groundbreaking approach to early detection by picking up early signs of pancreatic cancer through detecting changes in the blood. This is crucial as pancreatic cancer often shows no symptoms in its early stages, making early detection key to improving survival rates.  Thank you to Dr David Cox for highlighting pancreatic cancer as a critical area of healthcare with vast unmet medical need. 👉 Read the article here: https://lnkd.in/dvsTf_Yx (paywall) 👉 For more information on how Avantect is changing the landscape of cancer detection, visit our website or contact us: https://www.avantect.com/ #PancreaticCancerAwareness #EarlyDetectionSavesLives #PancreaticCancer

🌍 📢 We are excited to announce that Dave Mullarkey, CEO of ClearNote Health, will be attending Abu Dhabi Global Healthcare Week. Join him as he delves into the latest advancements in healthcare innovation and genomics. 🗓️ Dave will be participating in a panel on liquid biopsy technologies, organized by M42 Health, on Monday, May 13th. M42 is a leading force in driving healthcare innovation in the region, and we're eager to contribute to the discussions. Stay tuned for more details! 🤝 If you're attending the conference, we'd love to connect with you to explore the future of healthcare innovation. Contact us at: https://lnkd.in/dp-yahs9 #AbuDhabiGlobalHealthWeek #HealthcareInnovation #Genomics #LiquidBiopsy

Over the weekend, members of our team took part in #PanCAN #PurpleStride San Diego 2024, which brought together pancreatic cancer survivors, families, caregivers, researchers and supporters. Within this decade, pancreatic cancer is expected to be the second leading cause of cancer mortality in the United States. However, it’s been shown that diagnosis at an early stage, when patients have better treatment options, has the potential to increase survival rates by more than ten times. We're proud to be helping raise awareness of the impact of #pancreaticcancer and contributing to better patient outcomes for this devastating disease.

🧬 Happy #DNADay! 🧁 Today, we celebrate the remarkable milestones in genetic discovery that have shaped our understanding of human health, from the completion of the Human Genome Project in 2003 to the groundbreaking discovery of DNA's double helix in 1953. At ClearNote Health, we're honored to be playing a part in this journey. Our team is reflecting on the progress made and celebrating our contributions. With our proprietary epigenomic platform and cell-free DNA-based assays, we're driving early cancer detection by analyzing dynamic biological changes at the cellular level. While there's much more to do, we're inspired by the potential of genetics to transform healthcare and improve lives. Here's to continued innovation! #GeneticDiscovery #Epigenomics #EarlyCancerDetection

Together with ClearNote Health's blood-based #epigenomic platform and our industry-leading tissue and MRD assays, we hope to accelerate development of #PersonalizedTherapies and help our customers deepen their understanding of a patient’s response to #ImmunoTherapy. Want to learn more about our partnership with ClearNote Health? Come talk to us live at #AACR24 at booth 1637! Learn more from the press release: https://bit.ly/495d2Do.

📢 Don’t miss ClearNote Health at the American Association for Cancer Research annual meeting, April 5-10, San Diego. Our Senior Director, Head of Biopharma Development, Gulfem D. Guler, will be presenting data on our proprietary epigenomic platform, Virtuoso. Poster Title: “Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD1 treatment response and resistance biology in non-small cell lung cancer”  Session Title: Circulating Nucleic Acids 3 When: Apr 8, 2024 1:30 PM - 5:00 PM Location: Poster Section 41 Poster Board Number: 5 Our team will also be on hand at our partner Personalis, Inc.’s booth #1637. 🤝 Stop by and learn more about how Virtuoso can empower #drugdiscovery through 5hmC #epigenomics.

Our CEO, Dave Mullarkey, will be participating in a virtual fireside chat at William Blair's Innovator Series: Life Science Tools and Diagnostic event on April 4th, 11:00 AM, ET.    Tune in to learn how ClearNote Health’s proprietary #epigenomic platform technology measures dynamic biological changes in cells to provide an early signal of a developing cancer.   Discover how our Avantect tests are changing the paradigm of early cancer detection for pancreatic and ovarian cancer and how our epigenomic platform, Virtuoso, is empowering #drugdiscovery and development by offering dynamic insights into therapy response and resistance.   Not attending the event but wish to learn more? Contact us directly: https://lnkd.in/dp-yahs9

🏁 That’s a wrap on #TRICON, and what an amazing event it’s been! 🙏 Thank you to everyone who visited our booth, which was buzzing throughout the conference, or attended our presentation 'Epigenomic Tools for Early Cancer Detection & Therapy Response.' It has been incredibly exciting to engage in so many meaningful discussions about our epigenomic approach to early cancer detection.   If you missed us but are interested in learning more about Virtuoso, our epigenomic platform that is empowering drug discovery and development by offering dynamic insights into therapy response and resistance, please don’t hesitate to reach out: 🔗 https://lnkd.in/dp-yahs9 #epigenomics #earlycancerdetection